Penn Medicine Provider
Urology
Trinity J. Bivalacqua, MD, PhD
4.8
(449)
Accepting new patients
Sees patients age 18 and up
Penn Urology Perelman
View 1 additional location
Make an appointmentCall 215-662-2891

About me

  • Director, Urologic Oncology
  • Co-Director, Genitourinary Cancer Service Line, Abramson Cancer Center
  • Professor of Surgery at the Hospital of the University of Pennsylvania

I am a board-certified urologist with training and expertise in urologic cancers and sexual dysfunction. I am the Director of Urologic Oncology and Co-Director of the Genitourinary Cancer Service Line in the Abramson Cancer Center at Penn. My areas of expertise include the surgical management of prostate, bladder, penile, and upper tract urothelial cancers. I have expertise in open, endoscopic, laparoscopic and robotic surgery and am equipped to individualize treatment options for patients with a wide range of genitourinary malignancies. My other areas of focus include surgical management of erectile dysfunction (inflatable penile prosthesis) and continent urinary diversion (orthotopic neobladder). I strive to offer all my patients organ sparing approaches to treatment of their urologic cancers and my goal is to provide them with the best quality of life following complex cancer and reconstructive surgeries for advanced pelvic malignancies.

There are numerous reasons why patients come to Penn for the best cancer care. Our multidisciplinary urologic cancer team consists of a team of oncologists and surgeons who invest in all aspects of a patient's medical care including tumor sequencing, enrollment in clinical trials, performing world class cancer surgeries, and administering treatments from standard chemotherapy to targeted immunotherapies. The collaborative spirit at Penn is truly outstanding! My goal is to provide patients with a personalized approach to their urologic cancer treatment which is informed by tumor biology and patient preference.

My research program includes a basic translational research lab focusing on cancer immunology of urothelial cancer and tissue engineering approaches to regenerate the lower urinary tract. Our goal is to make discoveries in the research laboratory that can be translated into human clinical trials for management of bladder cancer and erectile dysfunction. I am also involved in surgical education and outcomes research as well as national guidelines panels. I have received multiple awards and recognition for my leadership in urologic oncology, sexual dysfunction and translational research including the American Urological Association (AUA) Rising Star Award and the AUA Gold Cystoscopy Award which is given to the individual who has contributed the most to the field of Urology within the first ten years of practice.

I may be known in the medical community for performing complex surgeries and cutting edge translational research but it's the intense satisfaction I get from helping both men and women with urologic cancers that excites me the most! For this reason, I work with a number of national society boards and advocacy groups including the AUA, the Sexual Medicine Society of North America, the Society of Urologic Oncology and the Bladder Cancer Advocacy Network, to help give back to patients who will benefit from standardization of treatment for urologic cancers and sexual dysfunction.

Education and training

  • Medical School: Tulane University
  • Residency: Johns Hopkins Hospital

What my patients think about me

Average Rating
4.8

451 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

June 2025
5.0
5.0
overall a very positive experience
June 2025
5.0
5.0
he is a person doctor. explain's everything. great doctor
June 2025
5.0
5.0
he was extremely helping me to make my decision to have surgery
June 2025
5.0
5.0
he was well prepared, having reviewed all the relevant information. i was using him as a second opinion. i will be perusing the rest of my care back in scranton, but his advice helps make me confident that i am going in the right direction.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Bivalacqua is a Penn Medicine physician. In New Jersey, providers are affiliated with Penn Medicine through Clinical Health Care Associates of New Jersey or Princeton Healthcare Affiliated Physicians, PC.

Qualifications and experience

My research

Singh AK, Wang R, Lombardo KA, Praharaj M, Bullen CK, Um P, Davis S, Komm O, Illei PB, Ordonez AA, Bahr M, Huang J, Gupta A, Psoter KJ, Jain SK, Bivalacqua TJ, Yegnasubramanian S, Bishai WR Dynamic single-cell RNA sequencing reveals BCG vaccination curtails SARS-CoV-2 induced disease severity and lung inflammation , bioRxiv: 2022 (Epub)

Harris TGW, Khandge P, Wu WJ, Leto Barone AA, Manyevitch R, Sholklapper T, Bivalacqua TJ, Burnett AL, Redett RJ 3rd, Gearhart JP Sexual health outcomes after penile reconstruction in the exstrophy-epispadias complex , Journal of Pediatric Urology: 2022 (Epub)

Einerhand SMH, Black AJ, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Zargar-Shoshtari K, Spiess PE, van Rhijn BWG, Black PC, Mertens LS Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer , World Journal of Urology, 40(11): 2022,2707-2715

Alam R, Patel SH, Kates MR, Singla N, Pavlovich CP, Allaf ME, Bivalacqua TJ, Pierorazio PM Differential changes in self-reported quality of life in elderly populations after diagnosis of a genitourinary malignancy , Urologic Oncology, 40(10): 2022,455.e1-455.e10

Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupret M, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Palou J, Kamat AM Intermediate-risk non-muscle-invasive bladder cancer: Updated consensus definition and management recommendations from the International Bladder Cancer Group , European Urology Oncology, 5(5): 2022,505-516

Gupta N, Patel HD, Taylor J, Borin JF, Jacobsohn K, Kenfield SA, Eggener SE, Price C, Davuluri M, Byrne N, Bivalacqua TJ, Loeb S Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes , Prostate Cancer & Prostatic Diseases, 25(3): 2022,444-452

Pohar KS, Patel S, Lotan Y, Trabulsi E, Woods M, Downs T, Huang WC, Jones J, Taylor J, O'Donnell M, Bivalacqua TJ, DeCastro J, Steinberg G, Kamat AM, Resnick MJ, Konety B, Schoenberg M, Jones JS, Daneshmand S; Flexible Blue Light Study Group Collaborators Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study , Urologic Oncology, 40(8): 2022,382.e1-382.e6

Sharma S, Rajani S, Hui J, Chen A, Bivalacqua T, Singh A Development of enzymatic-resistant and compliant decellularized extracellular matrixes via aliphatic chain modification for bladder tissue engineering , ACS Applied Materials & Interfaces, 14(33): 2022,37301-37315

Bivalacqua TJ, Allen BK, Brock GB, Broderick GA, Chou R, Kohler TS, Mulhall JP, Oristaglio J, Rahimi LL, Rogers ZR, Terlecki RP, Trost L, Yafi FA, Bennett NE Jr The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: An AUA/SMSNA Guideline , Journal of Urology, 208(1): 2022,43-52

Roumiguié M, Kamat AM, Bivalacqua TJ, Lerner SP, Kassouf W, Böhle A, Brausi M, Buckley R, Persad R, Colombel M, Lamm D, Palou-Redorta J, Soloway M, Brothers K, Steinberg G, Lotan Y, Sylvester R, Alfred Witjes J, Black PC International Bladder Cancer Group Consensus Statement on clinical trial design for patients with bacillus Calmette-Guérin-exposed high-risk non-muscle-invasive bladder cancer , European Urology, 82(1): 2022,34-46